High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 6, 2015, Pages 858-867

  Calais, Jérémie ^a,b   Dubray, Bernard ^b,c   Nkhali, Lamyaa ^a,b,c   Thureau, Sebastien ^a,b,c   Lemarignier, Charles ^a,b   Modzelewski, Romain ^a,b,c   Gardin, Isabelle ^a,b,c   Di Fiore, Frederic ^a   Michel, Pierre ^a   Vera, Pierre ^a,b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c CENTRE HENRI BECQUEREL   (France)

Author keywords

FDG PET CT; High FDG uptake; Local relapse; Oesophageal cancer; Radiotherapy; Target volume

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTINUOUS INFUSION; DRUG UPTAKE; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; AGED; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; TUMOR RECURRENCE;

AGED; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84943699099     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3004-y     Document Type: Article

References (42)

1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet 2013;381:400–12.
2. Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer–a meta-analysis of the randomized trials. Cancer Treat Rev 2012;38:599–604.
3. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160–8.
4. Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol 2012;23:1095–103.
5. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167–74.
6. Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, et al. Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer 2006;95:705–9.
7. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012;118:2632–40.
8. Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 2012;82:468–74.
9. Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 2005;77:247–53.
10. Fu W-H, Wang L-H, Zhou Z-M, Dai J-R, Hu Y-M, Zhao L-J. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. World J Gastroenterol 2004;10:1098–102.
11. Kole TP, Aghayere O, Kwah J, Yorke ED, Goodman KA. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2012;83:1580–6.
12. Martin S, Chen JZ, Rashid Dar A, Yartsev S. Dosimetric comparison of helical tomotherapy, RapidArc, and a novel IMRT & Arc technique for esophageal carcinoma. Radiother Oncol 2011;101:431–7.
13. Wu VWC, Sham JST, Kwong DLW. Inverse planning in three-dimensional conformal and intensity-modulated radiotherapy of mid-thoracic oesophageal cancer. Br J Radiol 2004;77:568–72.
14. Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 2011;81:1336–42.
15. Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med 2012;53:864–71.
16. Van Westreenen HL, Westerterp M, Bossuyt PMM, Pruim J, Sloof GW, van Lanschot JJB, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004;22:3805–12.
17. Lambrecht M, Haustermans K. Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiother Oncol 2010;96:339–46.
18. Yu W, Fu X-L, Zhang Y-J, Xiang J-Q, Shen L, Jiang G-L, et al. GTV spatial conformity between different delineation methods by 18FDG PET/CT and pathology in esophageal cancer. Radiother Oncol 2009;93:441–6.
19. Aerts HJWL, van Baardwijk AAW, Petit SF, Offermann C, van Loon J, Houben R, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386–92.
20. Aerts HJ, Bussink J, Oyen WJ, van Elmpt W, Folgering AM, Emans D, et al. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer 2012;75:73–6.
21. van den Bogaard J, Janssen MHM, Janssens G, Buijsen J, Reniers B, Lambin P, et al. Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer. Radiother Oncol 2011;99:137–41.
22. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593–8.
23. Paidpally V, Mercier G, Shah BA, Senthamizhchelvan S, Subramaniam RM. Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors. AJR Am J Roentgenol 2014;202:406–12.
24. Di Fiore F, Blondin V, Hitzel A, Edet-Sanson A, Benyoucef A, Huet E, et al. 18F-fluorodeoxyglucose positron emission tomography after definitive chemoradiotherapy in patients with oesophageal carcinoma. Dig Liver Dis 2012;44:875–9.
25. Palie O, Michel P, Ménard J-F, Rousseau C, Rio E, Bridji B, et al. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging 2013;40:1345–55.
26. Lemarignier C, Di Fiore F, Marre C, Hapdey S, Modzelewski R, Gouel P, et al. Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2014;41:2008–16. doi:10.1007/s00259-014-2839-y.
27. Ourselin S, Roche A, Prima S, Ayache N. Block matching: a general framework to improve robustness of rigid registration of medical images. In: Delp SL, DiGoia AM, Jaramaz B, editors. MICCAI 2000 [Internet]. Heidelberg: Springer; 2000. p. 557–66. Available via http://link.springer.com/chapter/10.1007/978-3-540-40899-4_57. Accessed 2 Aug 2014.
28. Hanna GG, Hounsell AR, O’Sullivan JM. Geometrical analysis of radiotherapy target volume delineation: a systematic review of reported comparison methods. Clin Oncol (R Coll Radiol) 2010;22:515–25.
29. Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, et al. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3′-deoxy-3′-18F-fluorothymidine PET images in lung cancer. J Nucl Med 2013;54:1543–50.
30. Lu W, Tan S, Kim G, Feigenberg S, Zhang H, Kligerman S, et al. Pre-chemoradiation therapy FDG PET/CT cannot identify residual metabolically active areas in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2012;84:S312.
31. Hatt M, Visvikis D, Pradier O, Cheze-le Rest C. Baseline 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer. Eur J Nucl Med Mol Imaging 2011;38:1595–606.
32. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2010;17:115–22.
33. Shukovsky LJ, Fletcher GH. Time-dose and tumor volume relationships in the irradiation of squamous cell carcinoma of the tonsillar fossa. Radiology 1973;107:621–6.
34. Nkhali L, Thureau S, Edet-Sanson A, Doyeux K, Benyoucef A, Gardin I, et al. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: reducing target volumes to deliver higher radiotherapy doses. Acta Oncol 2014;1–7.
35. Vera P, Dubray B, Palie O, Buvat I, Hapdey S, Modzelewski R, et al. Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer. EJNMMI Res 2014;4:12.
36. Necib H, Garcia C, Wagner A, Vanderlinden B, Emonts P, Hendlisz A, et al. Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging. J Nucl Med 2011;52:354–61.
37. Hawkins MA, Aitken A, Hansen VN, McNair HA, Tait DM. Cone beam CT verification for oesophageal cancer – impact of volume selected for image registration. Acta Oncol 2011;50:1183–90.
38. Menzel C, Döbert N, Rieker O, Kneist W, Mose S, Teising A, et al. 18F-Deoxyglucose PET for the staging of oesophageal cancer: influence of histopathological subtype and tumour grading. Nuklearmedizin 2003;42:90–3.
39. Mees G, Dierckx R, Vangestel C, Laukens D, Van Damme N, Van de Wiele C. Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake? Mol Imaging 2013;12:49–58.
40. Van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392–8.
41. Huang T, Civelek AC, Li J, Jiang H, Ng CK, Postel GC, et al. Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer. J Nucl Med 2012;53:1262–8.
42. Wijsman R, Kaanders JH, Oyen WJ, Bussink J. Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography. Q J Nucl Med Mol Imaging 2013;57:244–56.